
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
PAREXEL International Corporation, an innovator of global biopharmaceutical services, introduced a new, dedicated division to help emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively. PAREXEL utilizes different strategies and services such as consulting, patient recruitment, trial execution, and Real World Evidence programs in order to help companies reach their objectives.
Read the full release






